Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 568

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Open access
Rohaan, Maartje W., Borch, Troels H., van den Berg, Joost H., Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H., Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H., Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M., Monberg, Tine J., Holmstroem, Rikke B., Wever, Lidwina D.V., van Dijk, Marloes, Grijpink-Ongering, Lindsay G., Valkenet, Ludy H.M., Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S.W., ten Ham, Renske M.T., Retèl, Valesca P., van Harten, Wim H., Lalezari, Ferry, van Tinteren, Harm, van der Veldt, Astrid A.M., Hospers, Geke A.P., Stevense-den Boer, Marion A.M., Suijkerbuijk, Karijn P.M., Aarts, Maureen J.B., Piersma, Djura, van den Eertwegh, Alfons J.M., de Groot, Jan-Willem B., Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J., Fiets, W. Edward, van den Berkmortel, Franchette W.P.J., Ellebaek, Eva, Hölmich, Lisbet R., van Akkooi, Alexander C.J., van Houdt, Winan J., Wouters, Michel W.J.M., van Thienen, Johannes V., Blank, Christian U., Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N., Donia, Marco, Svane, Inge Marie, Haanen, John B.A.G. · 2022 · New England Journal of Medicine

Abstract

BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. METHODS: TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. RESULTS: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression. CONCLUSIONS: In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2210233

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 568

Metadata

Authors
Rohaan, M. W., Borch, T. H., van den Berg, J. H., Met, Ö., Kessels, R., Geukes Foppen, M. H., Stoltenborg Granhøj, J., Nuijen, B., Nijenhuis, C., Jedema, I., van Zon, M., Scheij, S., Beijnen, J. H., Hansen, M., Voermans, C., Noringriis, I. M., Monberg, T. J., Holmstroem, R. B., Wever, L. D. V., van Dijk, M., Grijpink-Ongering, L. G., Valkenet, L. H. M., Torres Acosta, A., Karger, M., Borgers, J. S. W., ten Ham, R. M. T., Retèl, V. P., van Harten, W. H., Lalezari, F., van Tinteren, H., van der Veldt, A. A. M., Hospers, G. A. P., Stevense-den Boer, M. A. M., Suijkerbuijk, K. P. M., Aarts, M. J. B., Piersma, D., van den Eertwegh, A. J. M., de Groot, J.-W. B., Vreugdenhil, G., Kapiteijn, E., Boers-Sonderen, M. J., Fiets, W. E., van den Berkmortel, F. W. P. J., Ellebaek, E., Hölmich, L. R., van Akkooi, A. C. J., van Houdt, W. J., Wouters, M. W. J. M., van Thienen, J. V., Blank, C. U., Meerveld-Eggink, A., Klobuch, S., Wilgenhof, S., Schumacher, T. N., Donia, M., Svane, I. M., & Haanen, J. B. A. G.
Venue
New England Journal of Medicine
Published
2022-12-08
Volume
387
Issue
23
Pages
2113-2125
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4311584464
Cited by
568
References
35
FWCI
39.70
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.